Blood Cancer Journal

29 Apr, 2022

Dr. Rajesh Bollam

Image
AML Induction for Boards!
2012:
7+3 = Fit
LDAC/HMA = Not fit
2022:
7+3+gemtuzumab = Favorable [t(8;21),inv(16), NPM1+/FLT-, CEBPAx2]
7+3 = Intermediate risk
7+3+midostaurin = FLT3 ITD or TKD
CPX351 = >60, t-AML/MDS
Ven+HMA = Not fit or TP53/complex cyto

Add a comment